Safety and preliminary efficacy of argatroban plus dual antiplatelet therapy for acute mild to moderate ischemic stroke with large artery atherosclerosis
Open Access
- 8 June 2022
- journal article
- research article
- Published by Wiley in Brain and Behavior
- Vol. 12 (7) , e2664
Abstract
Objective: Previous studies suggest the benefit of dual antiplatelet therapy (DAPT) for acute ischemic stroke with large artery atherosclerosis (LAA) etiology, but there is no study about the effect of DAPT plus anticoagulant in this population.Methods: A prospective single arm trial was performed to determine the effect of DAPT combined with argatroban on acute mild to moderate ischemic stroke patients with LAA, which was compared with historical populations. The main outcome was the proportion of early neurological deterioration (END). The secondary outcomes included scores of 0 to 1 and 0 to 2 on the modified Rankin Scale (mRS) at 90 days, and changes in National Institutes of Health Stroke Scale (NIHSS) from baseline to day 7 after admission. The safety outcomes included intracranial hemorrhage at 7 days, organ hemorrhage, and all‐cause mortality at 90 days.Results: A total of 120 patients with argatroban plus DAPT were prospectively enrolled and 529 patients with only DAPT were retrospectively collected. There was no significant difference in baseline characteristics between groups. Compared with control group, combined treatment group had lower proportion of END (4.2% vs. 10.0%, adjusted p = .046), more reduction in NIHSS score from the baseline to day 7 after admission (1.06 ± 2.03 vs. 0.39 ± 1.97, adjusted p = .003), and higher proportion of mRS (0–2) at 90 days (87.5% vs. 79.2%, adjusted p = .048). No intracranial hemorrhage was found between groups.Conclusions: This is the first report that short‐term argatroban combined with DAPT seems to be safe and may effectively prevent END and improve neurological prognosis for acute mild to moderate ischemic stroke patients with LAA; however, interpretation of the conclusion required caution due to nonrandomized controlled trial with medium sample size.Keywords
This publication has 27 references indexed in Scilit:
- Clopidogrel Plus Aspirin Prevents Early Neurologic Deterioration and Improves 6-Month Outcome in Patients With Acute Large Artery Atherosclerosis StrokeClinical and Applied Thrombosis/Hemostasis, 2014
- A Comparative Study of Dual versus Monoantiplatelet Therapy in Patients with Acute Large-Artery Atherosclerosis StrokeJournal of Stroke and Cerebrovascular Diseases, 2014
- Thrombolysis for acute ischaemic strokeCochrane Database of Systematic Reviews, 2014
- Relevance of stroke subtype in vascular risk predictionNeurology, 2013
- Clopidogrel with Aspirin in Acute Minor Stroke or Transient Ischemic AttackNew England Journal of Medicine, 2013
- Antiplatelet therapy for acute ischaemic stroke2008
- Argatroban tPA Stroke StudyArchives of Neurology, 2006
- Comparison of Warfarin and Aspirin for Symptomatic Intracranial Arterial StenosisNew England Journal of Medicine, 2005
- Acute Ischemic Strokes Improving During the First 48 Hours of Onset: Predictability, Outcome, and Possible MechanismsStroke, 1997
- Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.Stroke, 1993